Astra challenges witnesses in Seroquel suit; Sepracor inks Xopenex deal with Teva;

> In a Delaware court, attorneys for drug maker AstraZeneca are challenging the findings of expert witnesses who claim the company's anti-psychotic drug Seroquel causes diabetes. Report

> Sepracor agreed to allow Teva Pharmaceutical to launch generic versions of its respiratory drug Xopenex in 2013 under terms of a patent lawsuit settlement. Report

> Reflecting recent rapid growth of off-label prescribing, 75 percent of U.S. health plans now reimburse patients for such treatments, according to a study by the Tufts Center for the Study of Drug Development. Release

> The FDA said it would allow patients with Amyotrophic Lateral Sclerosis, or ALS, access to Insmed's experimental drug Iplex. Report

> GlaxoSmithKline tapped generics marketing Prasco Laboratories to sell and distribute copycat versions of its products, the first of which will be a Prasco/GSK-labeled generic of Flonase nasal spray. Release

> Hong Kong's health department has instructed Marching Pharmaceutical to recall 216 products because their labelled expiration dates were not substantiated by laboratory data. Report

> Pharmaceutical and health care market research firm IMS Health elected Bradley Sheares to its board of directors. Report

> Novozymes Biopharma inked a deal with GE Healthcare to use the latter's technology in producing native, animal-free protein A. Report

> Treating peripheral arterial disease with drug-eluting stents may save lives and limbs in people with severely obstructed arteries, Greek researchers have found. Report

> As small and large drug developers continue to cut costs and jobs, there are a growing number of out-of-work biotech types looking for their next job. And on Monday morning over 1,000 of those jobless biotech workers packed a South San Francisco Life Science Career Fair looking for new careers to replace those they've lost. Report

> With Genentech and Roche seen moving closer to a deal and the Schering-Plough tie-up with Merck commanding the attention of the drug industry's analysts, the Wall Street Journal lays out a consensus that the consolidation underway now will soon force more M&A activity in biotechnology. Report

> Progen shareholders have turned a cold shoulder to management's proposal to merge the cash-rich, product-poor company with Avexa. Most of the proxy votes went against the merger. Report

> The credit crunch has caused a number of biotech investors to demand that struggling biotech companies should shut down and distribute any remaining funds rather than try and find a new way forward. Report

And Finally... The National Institute for Health and Clinical Excellence (NICE) will go head-to-head with GlaxoSmithKline on the issue of drug pricing at the 2009 Bupa Health Debate on March 25, at a time when they are arguing heatedly over the cost of breast cancer treatment Tyverb. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.